Naeja

Naeja-RGM Pharmaceuticals is a Canadian drug discovery company based in Edmonton, Alberta, specializing in the development of novel antibiotics to combat multi-drug resistant (MDR) infections. Founded in 2016 as a successor to the original NAEJA Pharmaceutical Inc., the company continues the legacy of Dr. Ronald G. Micetich, the co-inventor of the widely used beta-lactamase inhibitor Tazobactam. Naeja-RGM leverages an extensive proprietary library of chiral compounds and deep expertise in beta-lactamase inhibitors to advance its internal pipeline and support global pharmaceutical partnerships. Its research focus includes next-generation antimicrobial agents targeting Gram-negative and Gram-positive bacteria, particularly the ESKAPE pathogens. The company operates as both a drug developer and a specialized contract research organization, collaborating with major pharmaceutical firms on infectious disease programs.